International Bordetella pertussis assay standardization and harmonization meeting report. Centers for Disease Control and Prevention, Atlanta, Georgia, United States, 19-20 July 2007

Vaccine

Volumn 27, Issue 6, 2009, Pages 803-814

  Tondella, M L ^a   Carlone, G M ^a   Messonnier, N ^a   Quinn, C P ^a   Meade, B D ^b   Burns, D L ^c   Cherry, J D ^d   Guiso, N ^e   Hewlett, E L ^f   Edwards, K M ^g   Xing, D ^h   Giammanco, A ⁱ   Wirsing von Konig C H ^j   Han, L ^k   Hueston, L ^l   Robbins, J B ^m   Powell, M ⁿ   Mink, C M ^d   Poolman, J T ^o   Hildreth, S W ^p   Lynn, F ^q   Morris, A ^r   more..

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Meade Biologics   (United States)

^c CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e INSTITUT PASTEUR   (France)

^f UNIVERSITY OF VIRGINIA   (United States)

^g VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^h NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

ⁱ UNIVERSITY OF PALERMO   (Italy)

^j Klinikum Krefeld   (Germany)

^k MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH   (United States)

^l Western Sydney Area Health Service   (Australia)

^m EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

ⁿ MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^o GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^p SANOFI PASTEUR   (France)

^q NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^r DALHOUSIE UNIVERSITY   (Canada)

more..

Author keywords

Bordetella pertussis; ELISA; Pertussis vaccines; Standardization of serologic assays; Whooping cough

Indexed keywords

ANTIGEN; DIPHTHERIA PERTUSSIS TETANUS VACCINE; PERTUSSIS TOXIN; PERTUSSIS VACCINE;

BORDETELLA PERTUSSIS; CLINICAL TRIAL; CONFERENCE PAPER; CONSENSUS; DISEASE CONTROL; DRUG EFFICACY; HUMAN; IMMUNOASSAY; IMMUNOGENICITY; IMMUNOLOGY; LABORATORY; OUTCOME ASSESSMENT; PERTUSSIS; PRIORITY JOURNAL; PROPHYLAXIS; SERODIAGNOSIS; STANDARDIZATION; UNITED STATES; WORLD HEALTH ORGANIZATION;

BORDETELLA PERTUSSIS; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); CLINICAL LABORATORY TECHNIQUES; HUMANS; UNITED STATES; WHOOPING COUGH;

EID: 58549106547     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.11.072     Document Type: Conference Paper

References (94)

1. CDC. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR Recomm Rep 55 RR-17 (2006) 1-37
2. CDC. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 55 RR-3 (2006) 1-34
3. CDC. Outbreaks of respiratory illness mistakenly attributed to pertussis-New Hampshire, Massachusetts, and Tennessee, 2004-2006. MMWR 56 33 (2007) 837-842
4. Edwards K.M. Overview of pertussis: focus on epidemiology, sources of infection, and long term protection after infant vaccination. Pediatr Infect Dis J 24 June (6 Suppl.) (2005) S104-S108
5. Roush S.W., and Murphy T.V. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA 298 November (18) (2007) 2155-2163
6. Wirsing von Konig C.H., Halperin S., Riffelmann M., and Guiso N. Pertussis of adults and infants. Lancet Infect Dis 2 December (12) (2002) 744-750
7. Wirsing von Konig C.H., Campins-Marti M., Finn A., Guiso N., Mertsola J., and Liese J. Pertussis immunization in the global pertussis initiative European region: recommended strategies and implementation considerations. Pediatr Infect Dis J 24 May (5 Suppl.) (2005) S87-92
8. Forsyth K.D., Campins-Marti M., Caro J., Cherry J.D., Greenberg D., Guiso N., et al. New pertussis vaccination strategies beyond infancy: recommendations by the global pertussis initiative. Clin Infect Dis 39 December (12) (2004) 1802-1809
9. de Melker H.E., Schellekens J.F., Neppelenbroek S.E., Mooi F.R., Rumke H.C., and Conyn-van Spaendonck M.A. Reemergence of pertussis in the highly vaccinated population of the Netherlands: observations on surveillance data. Emerg Infect Dis 6 July-August (4) (2000) 348-357
10. Halperin S.A. The control of pertussis-2007 and beyond. N Engl J Med 356 January (2) (2007) 110-113
11. Mattoo S., and Cherry J.D. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 18 April (2) (2005) 326-382
12. Crowcroft N.S., Stein C., Duclos P., and Birmingham M. How best to estimate the global burden of pertussis?. Lancet Infect Dis 3 July (7) (2003) 413-418
13. Forsyth K., Nagai M., Lepetic A., and Trindade E. Pertussis immunization in the global pertussis initiative international region: recommended strategies and implementation considerations. Pediatr Infect Dis J 24 May (5 Suppl.) (2005) S93-S97
14. Rothstein E., and Edwards K. Health burden of pertussis in adolescents and adults. Pediatr Infect Dis J 24 May (5 Suppl.) (2005) S44-S47
15. Cherry J.D. The epidemiology of pertussis: a comparison of the epidemiology of the disease pertussis with the epidemiology of Bordetella pertussis infection. Pediatrics 115 May (5) (2005) 1422-1427
16. Wendelboe A.M., and Van Rie A. Diagnosis of pertussis: a historical review and recent developments. Expert Rev Mol Diagn 6 November (6) (2006) 857-864
17. Cherry J.D., Grimprel E., Guiso N., Heininger U., and Mertsola J. Defining pertussis epidemiology: clinical, microbiologic and serologic perspectives. Pediatr Infect Dis J 24 May (5 Suppl.) (2005) S25-34
18. Muller F.M., Hoppe J.E., and Wirsing von Konig C.H. Laboratory diagnosis of pertussis: state of the art in 1997. J Clin Microbiol 35 October (10) (1997) 2435-2443
19. Riffelmann M., Wirsing von Konig C.H., Caro V., and Guiso N. Nucleic Acid amplification tests for diagnosis of Bordetella infections. J Clin Microbiol 43 October (10) (2005) 4925-4929
20. Fry N.K., Tzivra O., Li Y.T., McNiff A., Doshi N., Maple P.A., et al. Laboratory diagnosis of pertussis infections: the role of PCR and serology. J Med Microbiol 53 June (Pt 6) (2004) 519-525
21. Tatti K.M., Wu K.H., Tondella M.L., Cassiday P.K., Cortese M.M., Wilkins P.P., et al. Development and evaluation of dual-target real-time polymerase chain reaction assays to detect Bordetella spp. Diagn Microbiol Infect Dis 61 July (3) (2008) 264-272
22. Lievano F.A., Reynolds M.A., Waring A.L., Ackelsberg J., Bisgard K.M., Sanden G.N., et al. Issues associated with and recommendations for using PCR to detect outbreaks of pertussis. J Clin Microbiol 40 August (8) (2002) 2801-2805
23. Muyldermans G., Soetens O., Antoine M., Bruisten S., Vincart B., Doucet-Populaire F., et al. External quality assessment for molecular detection of Bordetella pertussis in European laboratories. J Clin Microbiol 43 January (1) (2005) 30-35
24. Register K.B., and Sanden G.N. Prevalence and sequence variants of IS481 in Bordetella bronchiseptica: implications for IS481-based detection of Bordetella pertussis. J Clin Microbiol 44 December (12) (2006) 4577-4583
25. Olin P., Hallander H.O., Gustafsson L., Reizenstein E., and Storsaeter J. How to make sense of pertussis immunogenicity data. Clin Infect Dis 33 December (Suppl. 4) (2001) S288-S291
26. Meyer C.U., Zepp F., Decker M., Lee M., Chang S.J., Ward J., et al. Cellular immunity in adolescents and adults following acellular pertussis vaccine administration. Clin Vaccine Immunol 14 March (3) (2007) 288-292
27. Storsaeter J., Hallander H.O., Gustafsson L., and Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 16 December (20) (1998) 1907-1916
28. Cherry J.D., Gornbein J., Heininger U., and Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 16 December (20) (1998) 1901-1906
29. Cherry J.D. Epidemiology of pertussis. Pediatr Infect Dis J 25 April (4) (2006) 361-362
30. Njamkepo E., Rimlinger F., Thiberge S., and Guiso N. Thirty-five years' experience with the whole-cell pertussis vaccine in France: vaccine strains analysis and immunogenicity. Vaccine 20 January (9-10) (2002) 1290-1294
31. Baron S., Njamkepo E., Grimprel E., Begue P., Desenclos J.C., Drucker J., et al. Epidemiology of pertussis in French hospitals in 1993 and 1994: thirty years after a routine use of vaccination. Pediatr Infect Dis J 17 May (5) (1998) 412-418
32. Grimprel E., Baron S., Levy-Bruhl D., Garnier J.M., N'Jamkepo E., Guiso N., et al. Influence of vaccination coverage on pertussis transmission in France. Lancet 354 November (9191) (1999) 1699-1700
33. Gilberg S., Njamkepo E., Du Chatelet I.P., Partouche H., Gueirard P., Ghasarossian C., et al. Evidence of Bordetella pertussis infection in adults presenting with persistent cough in a french area with very high whole-cell vaccine coverage. J Infect Dis 186 August (3) (2002) 415-418
34. Wendelboe A.M., Njamkepo E., Bourillon A., Floret D.D., Gaudelus J., Gerber M., et al. Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J 26 April (4) (2007) 293-299
35. Caro V., Hot D., Guigon G., Hubans C., Arrive M., Soubigou G., et al. Temporal analysis of French Bordetella pertussis isolates by comparative whole-genome hybridization. Microbes Infect 8 July (8) (2006) 2228-2235
36. Calendrier vaccinal 2008. Avis du Haut conseil de la santé publique. Bull Epidemiol Heb 2008;16-17:1-20.
37. Bonmarin I, Levy-Bruhl D, Baron S, Guiso N, Njamkepo E, Caro V. Pertussis surveillance in French hospitals: results from a 10 year period. Euro Surveill; 2007.
38. Schmitt H.J., von Konig C.H., Neiss A., Bogaerts H., Bock H.L., Schulte-Wissermann H., et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA 275 January (1) (1996) 37-41
39. Liese J.G., Meschievitz C.K., Harzer E., Froeschle J., Hosbach P., Hoppe J.E., et al. Efficacy of a two-component acellular pertussis vaccine in infants. Pediatr Infect Dis J 16 November (11) (1997) 1038-1044
40. Hewlett E.L. A commentary on the pathogenesis of pertussis. Clin Infect Dis 28 June (Suppl. 2) (1999) S94-S98
41. Toyota T., Kai Y., Kakizaki M., Sakai A., Goto Y., Yajima M., et al. Effects of islet-activating protein (IAP) on blood glucose and plasma insulin in healthy volunteers (phase 1 studies). Tohoku J Exp Med 130 February (2) (1980) 105-116
42. Meade B.D., Kind P.D., and Manclark C.R. Lymphocytosis-promoting factor of Bordetella pertussis alters mononuclear phagocyte circulation and response to inflammation. Infect Immun 46 December (3) (1984) 733-739
43. Hodge G., Hodge S., Markus C., Lawrence A., and Han P. A marked decrease in l-selectin expression by leucocytes in infants with Bordetella pertussis infection: leucocytosis explained?. Respirology (Carlton, Vic) 8 June (2) (2003) 157-162
44. Hudnall S.D., and Molina C.P. Marked increase in l-selectin-negative T cells in neonatal pertussis. The lymphocytosis explained?. Am J Clin Pathol 114 July (1) (2000) 35-40
45. Schneider O.D., Weiss A.A., and Miller W.E. Pertussis toxin utilizes proximal components of the T-cell receptor complex to initiate signal transduction events in T cells. Infect Immun 75 August (8) (2007) 4040-4049
46. Tonon S., Goriely S., Aksoy E., Pradier O., Del Giudice G., Trannoy E., et al. Bordetella pertussis toxin induces the release of inflammatory cytokines and dendritic cell activation in whole blood: impaired responses in human newborns. Eur J Immunol 32 November (11) (2002) 3118-3125
47. Abramson T., Kedem H., and Relman D.A. Proinflammatory and proapoptotic activities associated with Bordetella pertussis filamentous hemagglutinin. Infect Immun 69 April (4) (2001) 2650-2658
48. Confer D.L., and Eaton J.W. Phagocyte impotence caused by an invasive bacterial adenylate cyclase. Science 217 September (4563) (1982) 948-950
49. Khelef N., Zychlinsky A., and Guiso N. Bordetella pertussis induces apoptosis in macrophages: role of adenylate cyclase-hemolysin. Infect Immun 61 October (10) (1993) 4064-4071
50. Pearson R.D., Symes P., Conboy M., Weiss A.A., and Hewlett E.L. Inhibition of monocyte oxidative responses by Bordetella pertussis adenylate cyclase toxin. J Immunol 139 October (8) (1987) 2749-2754
51. Bassinet L., Fitting C., Housset B., Cavaillon J.M., and Guiso N. Bordetella pertussis adenylate cyclase-hemolysin induces interleukin-6 secretion by human tracheal epithelial cells. Infect Immun 72 September (9) (2004) 5530-5533
52. Perkins D.J., Gray M.C., Hewlett E.L., and Vogel S.N. Bordetella pertussis adenylate cyclase toxin (ACT) induces cyclooxygenase-2 (COX-2) in murine macrophages and is facilitated by ACT interaction with CD11b/CD18 (Mac-1). Mol Microbiol 66 November (4) (2007) 1003-1015
53. Ausiello C.M., Lande R., Stefanelli P., Fazio C., Fedele G., Palazzo R., et al. T-cell immune response assessment as a complement to serology and intranasal protection assays in determining the protective immunity induced by acellular pertussis vaccines in mice. Clin Diagn Lab Immunol 10 July (4) (2003) 637-642
54. Mills K.H., Ryan M., Ryan E., and Mahon B.P. A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infect Immun 66 February (2) (1998) 594-602
55. Watanabe M., Komatsu E., Sato T., and Nagai M. Evaluation of efficacy in terms of antibody levels and cell-mediated immunity of acellular pertussis vaccines in a murine model of respiratory infection. FEMS Immunol Med Microbiol 33 July (3) (2002) 219-225
56. CDC. Pertussis vaccination: Use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 46 RR-7 (1997) 1-25
57. Edwards K.M., Meade B.D., Decker M.D., Reed G.F., Rennels M.B., Steinhoff M.C., et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics 96 September (3 Pt 2) (1995) 548-557
58. Baughman A.L., Bisgard K.M., Edwards K.M., Guris D., Decker M.D., Holland K., et al. Establishment of diagnostic cutoff points for levels of serum antibodies to pertussis toxin, filamentous hemagglutinin, and fimbriae in adolescents and adults in the United States. Clin Diagn Lab Immunol 11 November (6) (2004) 1045-1053
59. Lynn F., Reed G.F., and Meade B.D. Collaborative study for the evaluation of enzyme-linked immunosorbent assays used to measure human antibodies to Bordetella pertussis antigens. Clin Diagn Lab Immunol 3 November (6) (1996) 689-700
60. Watanabe M., Connelly B., and Weiss A.A. Characterization of serological responses to pertussis. Clin Vaccine Immunol 13 Mar (3) (2006) 341-348
61. de Melker H.E., Versteegh F.G., Conyn-Van Spaendonck M.A., Elvers L.H., Berbers G.A., van Der Zee A., et al. Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis. J Clin Microbiol 38 February (2) (2000) 800-806
62. Giammanco A., Chiarini A., Maple P.A., Andrews N., Pebody R., Gay N., et al. European Sero-Epidemiology Network: standardisation of the assay results for pertussis. Vaccine 22 December (1) (2003) 112-120
63. Marchant C.D., Loughlin A.M., Lett S.M., Todd C.W., Wetterlow L.H., Bicchieri R., et al. Pertussis in Massachusetts, 1981-1991: incidence, serologic diagnosis, and vaccine effectiveness. J Infect Dis 169 June (6) (1994) 1297-1305
64. Corbel M.J., Mastrantonio P., and Kreeftenberg J.G. Ad hoc Working Group on acellular pertussis vaccines, World Health Organisation, Geneva, 27-28 July 2000. Vaccine 20 November (3-4) (2001) 288-291
65. Osborne K., Weinberg J., and Miller E. The European Sero-Epidemiology Network. Euro Surveill 2 April (4) (1997) 29-31
66. Pebody R.G., Gay N.J., Giammanco A., Baron S., Schellekens J., Tischer A., et al. The seroepidemiology of Bordetella pertussis infection in Western Europe. Epidemiol Infect 133 February (1) (2005) 159-171
67. Wirsing von Konig C.H., Gounis D., Laukamp S., Bogaerts H., and Schmitt H.J. Evaluation of a single-sample serological technique for diagnosing pertussis in unvaccinated children. Eur J Clin Microbiol Infect Dis 18 May (5) (1999) 341-345
68. Simondon F., Iteman I., Preziosi M.P., Yam A., and Guiso N. Evaluation of an immunoglobulin G enzyme-linked immunosorbent assay for pertussis toxin and filamentous hemagglutinin in diagnosis of pertussis in Senegal. Clin Diagn Lab Immunol 5 March (2) (1998) 130-134
69. Kosters K., Riffelmann M., Dohrn B., and von Konig C.H. Comparison of five commercial enzyme-linked immunosorbent assays for detection of antibodies to Bordetella pertussis. Clin Diagn Lab Immunol 7 May (3) (2000) 422-426
70. Schellekens JBH, Verbakel J, Boshuis H, Elvers L, Meijer B, Van Houte A, Peeters M. Serodiagnosis of Pertussis with Commercial ELISA's. In: Microbiology ASo, editor. 42th ICAAC; 2002; San Diego, California, US: American Society of Microbiology; 2002.
71. Cherry J.D., Xing D.X., Newland P., Patel K., Heininger U., and Corbel M.J. Determination of serum antibody to Bordetella pertussis adenylate cyclase toxin in vaccinated and unvaccinated children and in children and adults with pertussis. Clin Infect Dis 38 February (4) (2004) 502-507
72. Sako W. Studies on pertussis immunization. J Pediatr 30 (1947) 29-40
73. Cherry J.D., Beer T., Chartrand S.A., DeVille J., Beer E., Olsen M.A., et al. Comparison of values of antibody to Bordetella pertussis antigens in young German and American men. Clin Infect Dis 20 May (5) (1995) 1271-1274
74. Stehr K., Cherry J.D., Heininger U., Schmitt-Grohe S., uberall M., Laussucq S., et al. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics 101 January (1 Pt 1) (1998) 1-11
75. Pittman M. Pertussis toxin: the cause of the harmful effects and prolonged immunity of whooping cough. A hypothesis. Rev Infect Dis 1 May-June (3) (1979) 401-412
76. Robbins J.B., Pittman M., Trollfors B., Lagergard T.A., Taranger J., and Schneerson R. Primum non nocere: a pharmacologically inert pertussis toxoid alone should be the next pertussis vaccine. Pediatr Infect Dis J 12 October (10) (1993) 795-807
77. Robbins J.B., Schneerson R., Bryla D.A., Trollfors B., Taranger J., and Lagergard T. Immunity to pertussis. Not all virulence factors are protective antigens. Adv Exp Med Biol 452 (1998) 207-218
78. Taranger J., Trollfors B., Bergfors E., Knutsson N., Sundh V., Lagergard T., et al. Mass vaccination of children with pertussis toxoid-decreased incidence in both vaccinated and nonvaccinated persons. Clin Infect Dis 33 October (7) (2001) 1004-1010
79. Xing D.K., Corbel M.J., Dobbelaer R., and Knezevic I. WHO Working Group on standardisation and control of acellular pertussis vaccines-report of a meeting held on 16-17 March 2006, St. Albans, United Kingdom. Vaccine 25 April (15) (2007) 2749-2757
80. Robbins J.B., Schneerson R., Keith J.M., Shiloach J., Miller M., and Trollors B. The rise in pertussis cases urges replacement of chemically-inactivated with genetically-inactivated toxoid for DTP. Vaccine 25 April (15) (2007) 2811-2816
81. Robbins J.B., Schneerson R., Trollfors B., Sato H., Sato Y., Rappuoli R., et al. The diphtheria and pertussis components of diphtheria-tetanus toxoids-pertussis vaccine should be genetically inactivated mutant toxins. J Infect Dis 191 January (1) (2005) 81-88
82. Taranger J., Trollfors B., Lagergard T., Sundh V., Bryla D.A., Schneerson R., et al. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. J Infect Dis 181 March (3) (2000) 1010-1013
83. Corbel M.J., Kreeftenberg J.G., and Knezevic I. WHO Working Group on the standardisation and control of pertussis vaccines-report of a meeting held on 6-7 May 2003, Ferney Voltaire, France. Vaccine 22 January (3-4) (2004) 293-300
84. Corbel M.J., Xing D.K., and Kreeftenberg J.G. Informal consultation with manufacturers and WHO Ad hoc working group on mouse protection models for acellular pertussis vaccines. National institute for biological standards, 12 November 1998. Biologicals 27 June (2) (1999) 189-193
85. Godfroid F., Denoel P., de Grave D., Schuerman L., and Poolman J. Diphtheria-tetanus-pertussis (DTP) combination vaccines and evaluation of pertussis immune responses. Int J Med Microbiol 294 October (5) (2004) 269-276
86. Storsaeter J., Blackwelder W.C., and Hallander H.O. Pertussis antibodies, protection, and vaccine efficacy after household exposure. Am J Dis Child 146 February (2) (1992) 167-172
87. Storsaeter J., Hallander H.O., Gustafsson L., and Olin P. Low levels of antipertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis. Vaccine 21 September (25-26) (2003) 3542-3549
88. Bassinet L., Gueirard P., Maitre B., Housset B., Gounon P., and Guiso N. Role of adhesins and toxins in invasion of human tracheal epithelial cells by Bordetella pertussis. Infect Immun 68 April (4) (2000) 1934-1941
89. Hellwig S.M., Rodriguez M.E., Berbers G.A., van de Winkel J.G., and Mooi F.R. Crucial role of antibodies to pertactin in Bordetella pertussis immunity. J Infect Dis 188 September (5) (2003) 738-742
90. Edwards K.M., and Decker M.D. Pertussis vaccines. In: Plotkin S.A., Orenstein W.A., and Offit P.A. (Eds). Vaccines. 5th ed. (2008), Saunders Elsevier pp. 467-517
91. Hoppenbrouwers K., Kanra G., Roelants M., Ceyhan M., Vandermeulen C., Yurdakok K., et al. Priming effect, immunogenicity and safety of an Haemophilus influenzae type b-tetanus toxoid conjugate (PRP-T) and diphtheria-tetanus-acellular pertussis (DTaP) combination vaccine administered to infants in Belgium and Turkey. Vaccine 17 February (7-8) (1999) 875-886
92. Poolman J.T., and Hallander H.O. Acellular pertussis vaccines and the role of pertactin and fimbriae. Expert Rev Vaccines 6 February (1) (2007) 47-56
93. WHO. Pertussis Vaccines-WHO Position Paper. Weekly Epidemiological Record (http://wwwwhoint/wer/en/). World Health Organization; 2005. p. 31-9.
94. Manclark C., Meade B.D., and Burstyn D.G. Serological responses to Bordetella pertussis. In: In Rose N., Friedman H., and Fahey J.L. (Eds). Manual of clinical laboratory immunology. 3rd ed. (1986), ASM, Washington, DC 338-3394